The added value of H 2 antagonists in premedication regimens during paclitaxel treatment

• Published in: British journal of cancer Vol. 124; no. 10; p. 1647
• Main Authors: Cox, Juul M, van Doorn, Leni, Malmberg, Ruben, Oomen-de Hoop, Esther, Bosch, Tessa M, van den Bemt, Patricia M L A, Boere, Ingrid A, Jager, Agnes, Mathijssen, Ron H J, van Leeuwen, Roelof W F
• Format: Journal Article
• Language: English
• Published: England 01.05.2021
• Subjects: Adult; Aged; Aged, 80 and over; Chemoprevention - adverse effects; Chemoprevention - methods; Clemastine - administration & dosage; Dexamethasone - administration & dosage; Drug Hypersensitivity - epidemiology; Drug Hypersensitivity - pathology; Drug Hypersensitivity - prevention & control; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Histamine H2 Antagonists - administration & dosage; Histamine H2 Antagonists - therapeutic use; Humans; Infusions, Intravenous; Male; Medical Futility; Middle Aged; Neoplasms - drug therapy; Neoplasms - epidemiology; Neoplasms - pathology; Netherlands - epidemiology; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Premedication - adverse effects; Premedication - methods; Ranitidine - administration & dosage; Ranitidine - therapeutic use; Severity of Illness Index; Treatment Outcome; Netherlands

Ranitidine, a histamine 2 blocker, is the standard of care to prevent hypersensitivity reactions (HSRs) caused by paclitaxel infusion. However, the added value of ranitidine in this premedication regimen is controversial. Therefore, we compared the incidence of HSRs during paclitaxel treatment betwe...